Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Radiotherapy + Immunotherapy in N2 NSCLC
NCT07320105Phase 4Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Started Jan 2026; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07320105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320105.